Comparison of the proportion of patients with low BMD, abnormal blood lipid and blood glucose levels, overweight and obesity between GC users and non-GC users
| RR value (GC users vs non-GC users) | Non-GC users | GC users | Grouping by duration of GC therapy | |||
|---|---|---|---|---|---|---|
| GCs<0.5 years | GCs 0.5–2 years | GCs >2 years | ||||
| BMD | ||||||
| Number of cases | 111 | 206 | 26 | 89 | 91 | |
| Low BMD, n (%) | 1.15 (0.74–1.78) | 23 (20.7) | 49 (23.8) | 4 (15.4) | 24 (27.0) | 21 (23.1) |
| Blood lipids | ||||||
| Number of cases | 61 | 129 | 22 | 68 | 39 | |
| Elevated CHOL, n (%) | 2.84 (0.66–12.35) | 2 (3.3) | 12 (9.3) | 2 (9.1) | 9 (13.2) | 1 (2.6) |
| Elevated TG, n (%) | 0.68 (0.31–1.51) | 9 (14.8) | 13 (10.1) | 2 (9.1) | 8 (11.8) | 3 (7.7) |
| Decreased HDL,* n (%) | 0.64 (0.11–3.75) | 2 (3.6) | 3 (2.3) | 0 | 2 (3.0) | 1 (2.6) |
| Elevated LDL,* n (%) | 2.18 (0.26–18.18) | 1 (2.5) | 4 (4.1) | 1 (4.5) | 3 (4.6) | 1 (2.6) |
| Blood glucose | ||||||
| Number of cases | 136 | 199 | 54 | 92 | 52 | |
| Elevated glucose, n (%) | 0.273 (0.05–1.39) | 5 (3.7) | 2 (1.0) | 0 | 2 (2.2) | 0 |
| BMI | ||||||
| Number of cases | 137 | 230 | 31 | 119 | 80 | |
| Overweight, n (%) | 0.74 (0.49–1.11) | 33 (24.1) | 41 (17.8) | 5 (16.1) | 20 (16.8) | 16 (20.0) |
| Obesity, n (%) | 1.64 (0.53–5.05) | 4 (2.9) | 11 (4.8) | 0 | 8 (6.7) | 3 (3.8) |
All the p values between the GC subgroup (GCs <0.5, 0.5–2 or >2 years) and non-GC users were over 0.05.
*Out of the patients who had their blood lipids tested after treatment, six cases missed the data of HDL, and eight cases missed the data of LDL.
BMD, bone mineral density; BMI, body mass index; CHOL, cholesterol; GC, glucocorticoid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RR, relative risk; TG, triglyceride.